Cipla receives EIR for Patalganga facility

Cipla announced that it has received Establishment Inspection Report (EIR) which indicates the closure of the inspection by United States Food and Drug Administration (USFDA) at its Patalganga (Maharashtra) manufacturing facility.

The inspection was held from November 4 to 13, 2019.

Headquartered in Mumbai, Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, which is primarily engaged in developing medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression as well as other medical conditions.

On Monday, the stock of the company closed at Rs 480.15, down by 0.02 per cent or Rs 0.10 per share. The intraday high was Rs 483.40 and intraday low was Rs 476.90. The 52-week high is Rs 585.50 and 52-week low is Rs 389.55 on BSE.